IBJNews

Lilly suing J&J for patent rights in Alzheimer's drug race

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.

Both companies have drugs in development that use antibodies to target the build-up of plaque in patients’ brains. Lilly argues its treatment, solanezumab, doesn’t infringe a patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development LLC, according to court documents.

“An effective treatment for Alzheimer’s Disease (AD) has been elusive, despite massive efforts to find one,” Indianapolis-based Lilly said in the documents. The trial, which started Wednesday, “could dictate whether Lilly’s treatment for AD is available to patients in the [United Kingdom] before the expiry of the patent in November 2018, or possibly longer.”

Drug companies are vying to find the first working treatment for a condition that is expected to affect 65 million people worldwide by 2030, causing loss of memory, mood changes, dementia and brain damage. There have been 101 clinical trial failures since 1998, according to the Pharmaceutical Research & Manufacturers of America.

“The patent is valid and the claimant is not entitled to a declaration of non-infringement,” Janssen said in court documents from the trial.

Lilly’s UK media relations team didn’t immediately respond to a phone call seeking comment. Greg Panico, a U.S. spokesman for Janssen, declined to immediately comment.

Janssen’s drug, bapineuzumab, cost more than $500 million to research and ended up “a costly failure,” Lilly lawyer Andrew Waugh told the court Wednesday, citing clinical trial results.

Lilly is proceeding with its treatment, he said. “One of the reasons it hasn’t failed is because it works by a different mechanism to that which is described in the patent.”

Derica Rice, Lilly’s chief financial officer, said in an April earnings call the company would hold another pivotal trial for solanezumab this year.

While solanezumab failed to meet the main goal of two large studies, an analysis of the data from that research found it did slow progression in people with milder stages of Alzheimer’s. The new study, looking only at those patients, will start by the third quarter of 2013, Lilly said in December.

Sanofi CEO Chris Viehbacher said earlier this month the French drugmaker won’t pursue an Alzheimer’s treatment because the science isn’t advanced enough to justify the cost.

The first Alzheimer’s drugs, if successful, would lead to a market worth $20 billion, Barbara Ryan, a former Deutsche Bank analyst estimated last year.

ADVERTISEMENT

  • Competitive drug companies
    Memo-Johnson and Johnson (Risperdal) and,Eli Lilly (Zyprexa) were competitive atypical antipsychotics that got both companies sued for hundreds of millions in damage claims.--Daniel Haszard Zyprexa victim.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I had read earlier this spring that Noodles & Co was going to open in the Fishers Marketplace (which is SR 37 and 131st St, not 141st St, just FYI). Any word on that? Also, do you happen to know what is being built in Carmel at Pennsylvania and Old Meridian? May just be an office building but I'm not sure.

  2. I'm sorry, but you are flat out wrong. There are few tracks in the world with the history of IMS and probably NO OTHER as widely known and recognized. I don't care what you think about the stat of Indy Car racing, these are pretty hard things to dispute.

  3. Also wondering if there is an update on the Brockway Pub-Danny Boy restaurant/taproom that was planned for the village as well?

  4. Why does the majority get to trample on the rights of the minority? You do realize that banning gay marriage does not rid the world of gay people, right? They are still going to be around and they are still going to continue to exist. The best way to get it all out of the spotlight? LEGALIZE IT! If gay marriage is legal, they will get to stop trying to push for it and you will get to stop seeing it all over the news. Why do Christians get to decide what is moral?? Why do you get to push your religion on others? How would legalizing gay marriage expose their lifestyle to your children? By the way, their lifestyle is going to continue whether gay marriage is legalized or not. It's been legal in Canada for quite a while now and they seem to be doing just fine. What about actual rules handed down by God? What about not working on Sundays? What about obeying your parents? What about adultery? These are in the 10 Commandments, the most important of God's rules. Yet they are all perfectly legal. What about divorce? Only God is allowed to dissolve a marriage so why don't you work hard to get divorce banned? Why do you get to pick and choose the parts of the Bible you care about?

  5. Look at the bright side. With the new Lowe's call center, that means 1000 jobs at $10 bucks an hour. IMS has to be drooling over all that disposable income. If those employees can save all their extra money after bills, in five years they can go to the race LIVE. Can you say attendance boost?

ADVERTISEMENT